Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

avatar
Stock Region Private ID: 71149648
No profile added yet
Follow
    La Rosa Holdings Corp. Withdraws Registration Statement on Form S-1.
    La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company overseeing five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, announced its decision to file a Request for Withdrawal of the Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”). This article delves into the details o...
    Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA.
    Ainos, Inc. (NASDAQ: AIMD, AIMDW), a diversified healthcare company focusing on novel AI-powered point-of-care testing (POCT) and VELDONA low-dose interferon therapeutics, has recently announced advancements in the clinical trials of its "Ainos Flora" device. This volatile organic compound (VOC) PO...
    Medicare Issues Final Coverage Determination for KidneyIntelX.dkd: A Detailed Overview.
    Renalytix plc, a company listed on NASDAQ under the ticker symbol RNLX and also on the London Stock Exchange as RENX, has announced a pivotal development in the coverage of its KidneyIntelX.dkd testing. On June 13, 2024, Medicare issued a final Local Coverage Determination (LCD) for KidneyIntelX.dkd, a diagnostic tool designed to aid in the ma...
    Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress.
    Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024...
    Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate.
    Vaxart, Inc. (Nasdaq: VXRT), a biotechnology company known for its innovative oral vaccines, has announced a significant milestone in the development of its COVID-19 oral pill vaccine candidate. The company received a project award valued at up to $453 million throug...
    Nexalin Technology's Gen-2 Neurostimulation Device Receives Approval in Brazil.
    On June 17, 2024, Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW), a company known for its innovative neurostimulation products, announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency (ANVISA). ANVISA is a regulatory body under the Br...
    Zapp Electric Vehicles Group Limited (Nasdaq: ZAPP) to Appoint Contract Manufacturing Partner for Sales of i300 in India.
    Zapp Electric Vehicles Group Limited (Nasdaq: ZAPP), commonly referred to as Zapp EV, has announced the signing of a memorandum of understanding with Bounce Electric 1 Private Limited (Bounce). This partnership marks a crucial step towards the appointment of Bounce as Zapp’s contract manufacturing partner for s...
    FSD Pharma Enters Exclusive Option Agreement With University Of Southern California To Evaluate Dietary Supplement Technology For Commercialization.
    On June 11, 2024, FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company focused on creating innovative biotech solutions, announced an exclusive option agreement with the University of Southern California (USC). This agreement grants FSD Pharma ...
    JanOne's Subsidiary, Alt5 Sigma, Reports 91% Year-Over-Year Increase in Transaction Volume.
    JanOne, a multifaceted healthcare and fintech organization, has announced that its subsidiary, Alt5 Sigma, has achieved significant growth in transaction volume. For the months of April and May 2024, Alt5 Sigma reported a combined transaction volume of US$289 million. This figure represents a substantial 91% increase compared to the US$151 million rec...
    BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program.
    BioRestorative Therapies, Inc. (NASDAQ:BRTX), a clinical-stage company focused on stem cell-based therapies, has announced that it is currently engaged in substantive discussions with an undisclosed commercial-stage regenerative medicine company. These discussions concern a potential licensing agree...